Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi

 Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi

Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi

Shots:

  • Pharming to pay €7.5M in two tranches to Sobi and will reacquire exclusive rights to commercialize Ruconest in all remaining territories, which includes all remaining 36 EU markets and will be effective from Jan 1, 2020
  • Pharming to cooperate with Sobi for the replacement of all contracts for distribution and other services as quickly as possible, and to transfer existing reimbursement approvals where possible
  • Ruconest (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema in EU, the US, Israel, and South Korea

Click here to­ read full press release/ article | Ref: Pharming | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post